Diabetes, Vol 46, Issue 11 1893-1897, Copyright © 1997 by American Diabetes Association
Association of HLA-DR, DQ genotype with different beta-cell functions at IDDM diagnosis in Japanese children
S Sugihara, T Sakamaki, S Konda, A Murata, K Wataki, Y Kobayashi, K Minamitani, S Miyamoto, N Sasaki and H Niimi
Department of Pediatrics, Chiba University School of Medicine, Japan.
Japanese IDDM patients have been demonstrated to have unique and different
HLA associations from white patients. To elucidate the effect of
HLA-associated genetic factors on the clinical heterogeneity of IDDM in
Japanese people, HLA-DRB1, DQA1, and DQB1 genotypes in 88 childhood-onset
Japanese IDDM patients were examined by polymerase chain
reaction-sequence-specific oligonucleotide (PCR-SSO) or sequence-specific
primers (SSP). Of the 88 IDDM patients, 26 (29.5%) had
DRB1*0405-DQA1*0302-DQB1*0401/X (DR4-DQ4/X), 38 (43.2%) had
DRB1*0901-DQA1*0302-DQB1*0303/X (DR9-DQ9/X), and 9 (10.2%) were DR4/9-DQ4/9
heterozygous in the present study (X does not contain protective alleles).
Clinical heterogeneity such as age distribution at onset, prevalence and
serum level of anti-GAD antibodies (GADAb), and residual pancreatic
beta-cell function after diagnosis were compared between patients with
HLA-DR4-DQ4 and DR9-DQ9. The frequency of DR9-DQ9 genotype was
significantly higher in the younger (0-10 years) than in the older (11-16
years) age-group of onset, but the frequency of DR4-DQ4 was higher in the
older (11-16 years) age-group. Although no association of DR-DQ genotypes
with the prevalence and serum level of GADAb was found among newly
diagnosed patients, long-standing DR9-DQ9 patients had significantly higher
levels of GADAb than those with DR4-DQ4. While no difference in time course
of serum C-peptide (CPR) levels was detected between GADAb+ and GADAb-
patients, a remarkable difference was demonstrated between DR9-DQ9 and
DR4-DQ4 patients. The residual pancreatic beta-cell function was retained
more in patients with DR4-DQ4 than in those with DR9-DQ9 at diagnosis
through 12-18 months after diagnosis. These results suggest that the
DR9-DQ9 genotype may induce stronger autoimmune destructive response
(T-helper 1 function) against target beta-cells than the DR4-DQ4 genotype
does. Our findings may warrant further studies on the association of
diabetogenic autoimmune response with HLA class II molecules and contribute
to a clarification of interracial differences in HLA-encoded susceptibility
to IDDM.